Cartesian Therapeutics (RNAC) Profit After Tax (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Profit After Tax of -$39.2 million for Q1 2026, down 121.24% year-over-year from $184.5 million in Q1 2025, and up 57.68% quarter-over-quarter from -$92.6 million in Q4 2025.
Cartesian Therapeutics (RNAC) Profit After Tax (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Profit After Tax data on file, last reported at -$39.2 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$39.2 million, down 121.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$151.8 million (down 296.17% YoY), and the FY2025 annual result was -$130.3 million, down 68.3% from the prior year.
- Profit After Tax advanced to -$39.2 million in Q1 2026 per RNAC's latest filing, from -$92.6 million in the prior quarter.
- Over five years, Profit After Tax peaked at $28.8 million in Q1 2022 and troughed at -$177.7 million in Q4 2023.
- A 5-year average of -$25.4 million and a median of -$11.4 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax sank 3114.73% in 2023, then surged 221.51% in 2024.
- A 5-year view of Profit After Tax shows it stood at $5.9 million in 2022, then slumped by 3114.73% to -$177.7 million in 2023, then jumped by 94.23% to -$10.3 million in 2024, then sank by 802.92% to -$92.6 million in 2025, then surged by 57.68% to -$39.2 million in 2026.
- Business Quant data shows RNAC's Profit After Tax at -$39.2 million in Q1 2026, -$92.6 million in Q4 2025, and -$35.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -39.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.18 Mn |
| Dec 31, 2025 | -92.58 Mn |
| Sep 30, 2025 | -35.90 Mn |
| Jun 30, 2025 | 15.89 Mn |
| Mar 31, 2025 | -17.71 Mn |
| Dec 31, 2024 | -10.25 Mn |
| Sep 30, 2024 | -24.18 Mn |
| Jun 30, 2024 | 13.84 Mn |
| Mar 31, 2024 | -56.82 Mn |
| Dec 31, 2023 | -177.66 Mn |
| Sep 30, 2023 | -9.00 Mn |
| Jun 30, 2023 | -11.39 Mn |
| Mar 31, 2023 | -21.66 Mn |
| Dec 31, 2022 | 5.89 Mn |
| Sep 30, 2022 | -7.89 Mn |
| Jun 30, 2022 | 8.60 Mn |
| Mar 31, 2022 | 28.78 Mn |
| Dec 31, 2021 | 12.24 Mn |
| Sep 30, 2021 | -17.89 Mn |
| Jun 30, 2021 | 4.57 Mn |